Thursday, 23 March 2017
Latest news
Main » Nektar Opioid Drug Does Well In Study (NKTR, EGLT)

Nektar Opioid Drug Does Well In Study (NKTR, EGLT)

21 March 2017

For the past month, Nektar Therapeutics's stock has been 13.14%, 27.26% for the last quarter, -19.48% for the past six months and 25.81% for the past 52 weeks. Strs Ohio raised its position in Nektar Therapeutics by 39.4% in the third quarter.

During the double-blind, randomized treatment phase, average pain scores increased more in the placebo arm than in the NKTR-181 arm at week 12 (1.46 for placebo vs. 0.92 for NKTR-181; P = 0.0019). Genesee Valley Trust Co. now owns 12,189 shares of the biopharmaceutical company's stock valued at $209,000 after buying an additional 54 shares during the last quarter. The Company's shares are trading 29.30% above their 50-day moving average and 108.00% above their 200-day moving average.

Session activity on Nektar Therapeutics (NASDAQ:NKTR) shares bumps the stock on today's most active list. The business earned $37.45 million during the quarter, compared to analysts' expectations of $40.83 million. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. The number of times the company missed analysts' estimates is 4. Nektar Therapeutics (NASDAQ:NKTR)'s EPS growth this year is -79.50% and the trailing 12-month EPS is $-1.10.

More news: State Senator Daniel Biss Announces Candidacy For Governor

Several research firms have recently commented on NKTR.

Sell-side analysts are offering a consensus "Buy" rating on shares of Glori Energy Inc.

Nektar Therapeutics (NASDAQ:NKTR)'s shares may have a significant upside to the consensus target of 20.00, but how has it been performing relative to the market? Analysts giving the company a rating of 3 would be indicating a Hold recommendation. Finally, BTIG Research began coverage on Nektar Therapeutics in a research report on Friday, January 6th. They now have a United States dollars 22 price target on the stock. The company's market capitalization is $2.38 billion. The company now has a consensus rating of "Buy" and a consensus target price of $21.29.

More news: Kickapoo's Jared Ridder Named Missouri's Gatorade Player Of The Year

The terrific clinical news caused traders to bid up shares. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Howard W. Robin sold 87,500 shares of the firm's stock in a transaction on Tuesday, January 17th. The disclosure for this sale can be found here. This showed the surprise of 11.1% in the last quarter earnings.

Nektar will discuss the results with the U.S. Food and Drug Administration to determine whether any further data is needed for the company to apply for approval. Considering the earnings reaction history, The Company has topped 83% percentage.

More news: Uncharted: The Lost Legacy Will Not Have A Nathan Drake Cameo

Nektar Opioid Drug Does Well In Study (NKTR, EGLT)